Total inhibin is a potential serum marker for epithelial ovarian cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 7, 2007, Pages 2526-2531

  Tsigkou, Anastasia ^a   Marrelli, Daniele ^a   Reis, Fernando M ^b   Luisi, Stefano ^a   Silva Filho, Agnaldo L ^b   Roviello, Franco ^a   Triginelli, Sérgio A ^b   Petraglia, Felice ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; INHIBIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BLOOD CHEMISTRY; BLOOD SAMPLING; BREAST CANCER; CANCER GRADING; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEROSA; STATISTICAL SIGNIFICANCE; STOMACH CANCER;

EID: 34447125107     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0235     Document Type: Article

References (24)

1. Bast Jr RC 1993 Perspectives on the future of cancer markers. Clin Chem 39:2444-2451
2. Berchuck A 1995 Biomarkers in the ovary. J Cell Biochem Suppl 23:223-226
3. Mason AJ, Hayflick JS, Ling N, Esch F, Ueno N, Ying SY, Guillemin R, Niall H, Seeburg PH 1985 Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-β. Nature 6047:659-663
4. Ying SY 1988 Inhibins, activins and follistatins: gonadal proteins modulating the secretion of FSH. Endocr Rev 9:267-293
5. Vale W, Rivier C, Hsueh A, Campen C, Meunier H, Bicsak T 1988 Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 44:1-34
6. Burger HG, Cahir N, Robertson DM, Groome NP, Dudley E, Green A, Dennerstein L 1998 Serum inhibins A and B fall differentially as FSH rises in perimenopausal women. Clin Endocrinol (Oxf) 48:809-813
7. Burger HG, Dudley EC, Hopper JL, Groome N, Guthrie JR, Green A, Dennerstein L 1999 Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 84:4025-4030
8. Petraglia F, Luisi S, Pautier P, Sabourin JC, Rey R, Lhomme C, Bidart JM 1998 Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors. J Clin Endocrinol Metab 83:1029-1034
9. Healy DL, Burger HG, Bouma J 1993 Elevated serum inhibin concentrations in postmenopausal women with ovarian tumours. N Engl J Med 329:1539-1542
10. Lambert-Messerlian GM, Steinhoff M, Zheng W, Canick JA, Gajewski WH, Seifer DB, Schneyer AL 1997 Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer. Gynecol Oncol 65:512-516
11. Robertson DM, Cahir N, Burger HG, Mamers P, Groome N 1999 Inhibin forms in serum from postmenopausal women with ovarian cancers. J Clin Endocrinol Metab 82:889-896
12. Robertson DM, Cahir N, Burger HG, Mamers P, McLoud PI, Pettersson K, McGuckin M 1999 Combined inhibin and CA125 assays in the detection of ovarian cancer. Clin Chem 45:651-658
13. Robertson DM, Stephenson T, Pruysers E, McCloud P, Tsigos A, Groome N, Mamers P, Burger HG 2002 Characterization of inhibin forms and their measurement by an inhibin α-subunit ELISA in serum from postmenopausal women with ovarian cancer. J Clin Endocrinol Metab 87:816-824
14. Groome NP, Illingworth PJ, O'Brien M, Cooke I, Ganesan TS, Baird DT, McNeilly AS 1994 Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immuno-assay. Clin Endocrinol (Oxf) 40:717-723
15. Shultz EK 1995 Multivariate receiver-operating characteristic curve analysis: prostate cancer screening as an example. Clin Chem 41:1248-1255
16. Huseby N, Nilssen O, Kanitz R 1997 Evaluation of two biological markers combined as a parameter of alcohol dependency. Alcohol Alcohol 32:731-737
17. Richardson WS, Wilson MC, Guyatt GH, Cook DJ, Nishikawa J 1999 Users' guides to the medical literature: XV. How to use an article about disease probability for differential diagnosis. Evidence-based medicine working group. JAMA 281:1214-1219
18. Khan KS, Khan SF, Nwosu CR, Arnott N, Chien PF 1999 Misleading authors' inferences in obstetric diagnostic test literature. Am J Obstet Gynecol 181:112-115
19. Robertson DM, Burger HG, Fuller PJ 2004 Inhibin/activin and ovarian cancer. Endocr Relat Cancer 11:35-49
20. Matzuk MM, Finegold MJ, Su J-GJ, Hsueh AJW, Bradley A 1992 Inhibin α is a tumour suppressor gene with gonadal specificity in mice. Nature 360:313-319
21. Cipriano SC, Chen L, Burns KH, Koff A, Matzuk MM 2001 Inhibin and p27 interacts to regulate gonadal tumorigenesis. Mol Endocrinol 15:985-996
22. Bargmann CI, Hung MC, Weinberg RA 1986 The neu oncogene encodes an epidermal growth factor receptor -related protein. Nature 319:226-230
23. Sicinski P, Donaher JL, Geng Y, Paker SB, Gardner H, Park MY, Robker RL 1996 Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384:470-474
24. Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJ 1998 Field cancerization: why late recurrent ovarian cancer is not recurrent. Am J Obstet Gynecol 178:641-649